Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.44 |
| ▸ | MAOA | P21397 | 4/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL28592905 | 0.98 | MAOB (0.46) | MAOBMAOAPTPN1CYP1A2CHRNB2 | |
| Formic Acid SCHEMBL28395993 | 0.88 | MAOB (0.49) | MAOBMAOAPTPN1CA2 | |
| Methylchromone SCHEMBL29387804 | 0.82 | MAOB (0.56) | MAOBMAOAPTPN1SMN1; SMN2 | |
| Methylchromone SCHEMBL25934 | 0.82 | MAOB (0.56) | MAOBMAOAPTPN1SMN1; SMN2 | |
| Methylchromone SCHEMBL29160528 | 0.81 | MAOB (0.55) | MAOBMAOAPTPN1SMN1; SMN2 | |
| Ethoxycarbonyl Group SCHEMBL29184215 | 0.79 | MAOB (0.47) | MAOBMAOAPTPN1CA2SMN1; SMN2 | |
| Methylchromone SCHEMBL3456497 | 0.75 | MAOB (0.49) | MAOBMAOAPTPN1SMN1; SMN2 | |
| SCHEMBL1133152 | 0.74 | CHRM2 (0.41) | MAOBMAOAPTPN1CYP1A2CHRNB2 | |
| SCHEMBL2490828 | 0.74 | CHRM2 (0.50) | MAOBMAOAPTPN1CA2FTO | |
| SCHEMBL23919117 | 0.73 | KCNA3 (0.46) | MAOACYP1A2KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473283-B2 | Compounds and their use | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-11-18 | — | — | US | claimed |
| WO-2025109563-A1 | SPIRO-HYDANTOIN DERIVATIVE EXHIBITING ADAMTS-4 INHIBITORY ACTIVITY, AND USE THEREOF | 서울대학교병원 | 2025-05-30 | — | — | WO | claimed |
| CN-119684263-A | Synthetic method of terpetinib and key intermediate thereof | 苏州莱安医药化学技术有限公司 | 2025-03-25 | — | — | CN | claimed |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-21 | — | — | US | claimed |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-14 | — | — | US | claimed |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-26 | — | — | US | claimed |
| US-11084771-B2 | Method for purifying phenol | LG CHEM, LTD. (KR) | 2021-08-10 | — | — | US | claimed |
| CN-108633275-B | Process for purifying phenol | 株式会社LG化学 | 2021-07-27 | — | — | CN | claimed |
| US-20210198170-A1 | METHOD FOR PURIFYING PHENOL | LG CHEM, LTD. (KR) | 2021-07-01 | — | — | US | claimed |
| CN-107188846-B | A kind of synthetic method of arylseleno heterocyclic compound | 温州医科大学 | 2019-08-20 | — | — | CN | claimed |
| EP-1153022-A1 | PROTHEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-14 | — | — | EP | claimed |
| WO-2000049011-A1 | PROTHEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-24 | — | — | WO | claimed |
| EP-1027344-A2 | PHARMACEUTICAL COMPOUNDS ISOLATED FROM ARISTOLOCHIA TALISCANA | PROTEOME SCIENCES PLC (GB) | 2000-08-16 | — | — | EP | claimed |
| WO-1999006388-A2 | PHARMACEUTICAL COMPOUNDS ISOLATED FROM ARISTOLOCHIA TALISCANA | PROTEOME SCIENCES PLC. (GB) | 1999-02-11 | — | — | WO | claimed |
| US-5459131-A | Renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1995-10-17 | — | — | US | claimed |
| US-5104869-A | Renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1992-04-14 | — | — | US | claimed |
| EP-0427939-A2 | Renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1991-05-22 | — | — | EP | claimed |
| EP-0147044-B1 | BENZOFURANCARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | ADRIA LABORATORIES INC. (US) | 1990-04-25 | — | — | EP | claimed |
| US-4888353-A | Carboxamides useful as antiemetic or antipsychotic agents | ERBAMONT, INC. (US) | 1989-12-19 | — | — | US | claimed |
| EP-0147044-A2 | Benzofurancarboxamides, process for their preparation and pharmaceutical preparations containing them | ADRIA LABORATORIES INC. (US) | 1985-07-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | MAOB 517/4885MAOA 527/4885PTPN1 4269/4885 |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | MAOB 517/4885MAOA 527/4885PTPN1 4269/4885 |
| US-11084771-B2 | Method for purifying phenol | HACL2, GNPAT, ACACB | MAOB 325/4885MAOA 321/4885PTPN1 2636/4885 |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | MAOB 517/4885MAOA 527/4885PTPN1 4269/4885 |
| US-12473283-B2 | Compounds and their use | LSS, PGLS, LDHB | MAOB 917/4885MAOA 2023/4885PTPN1 2140/4885 |
| US-20210198170-A1 | METHOD FOR PURIFYING PHENOL | HACL2, ACACB, MBOAT4 | MAOB 475/4885MAOA 536/4885PTPN1 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.